Tech Company Financing Transactions
ViewsML Funding Round
On 4/20/2026, ViewsML announced $4.9 million in Seed funding from Wittington Ventures, Continuum Health Ventures and Debiopharm Diagnostics.
Transaction Overview
Company Name
Announced On
4/20/2026
Transaction Type
Venture Equity
Amount
$4,900,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to accelerate commercialization of its AI-driven virtual biomarker staining platform, expand its strategic partnerships, advance clinical validation of virtual biomarker panels, and grow its engineering, scientific, and commercial teams.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
550 Burrard Street 2900
Vancouver, BC, V6C 0A3
Canada
Vancouver, BC, V6C 0A3
Canada
Phone
Website
Email Address
Overview
ViewsML is dedicated to leveraging the power of AI to accelerate the delivery of precision medicines and make them accessible to patients worldwide. ViewsML uses virtual biomarker staining in AI-driven diagnostics, discovering deeper cell-level insights for better patient outcomes. ViewsML uses deep learning to eliminate physical staining, delivering virtual results in seconds at a fraction of the cost, all the while fitting into existing workflows.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kenneth To
Chief Medical Officer
Rafay Azhar
Chief Scientific Officer
Christopher Jackson
Chief Technical Officer
George Hennen
VP - Bus. Development
Keith Jalbert
Browse more venture capital transactions:
Prev: 4/20/2026: Cadre Energy Solutions venture capital transaction
Next: 4/20/2026: Sage Haven venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC transactions reported here are sourced from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs